85
Participants
Start Date
July 30, 2019
Primary Completion Date
January 31, 2026
Study Completion Date
January 31, 2026
CUE-101
CUE-101 is a novel biologic to treat HPV - driven recurrent / metastatic head and neck cancer given as monotherapy in parts A\&B and in combination in Parts C\&D according to the schedule described in the protocol.
KEYTRUDA®, Pembrolizumab
KEYTRUDA® is first-line therapy in HPV16 and HLA A\*0201-positive recurrent and/or metastatic HNSCC patients given in combination with CUE-101 in Parts C\&D according to the schedule described in the protocol.
Memorial Sloan Kettering Cancer Center, New York
George Washington University Cancer Center, Washington D.C.
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore
Emory University School of Medicine, Atlanta
Moffitt Cancer Center, Tampa
Affiliated Oncologists, LLC, Chicago
Vanderbilt-Ingram Cancer Center (VICC), Nashville
Gabrail Cancer Center, Canton
University of Michigan, Ann Arbor
Barbara Karmanos Cancer Center/ Wayne State University School of Medicine, Detroit
Washington University, St Louis
University of Texas MD Anderson Cancer Center, Houston
University of Arizona, Tucson
Stanford University Medical Center, Palo Alto
University of Washington School of Medicine, Seattle
Yale School of Medicine, New Haven
Massachusetts General Hospital, Boston
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Cue Biopharma
INDUSTRY